Skip to main content
SpringerLink
Log in

Following the six principles developed by the STAY initiative may improve treatment adherence in patients with schizophrenia

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Problems with adherence to medication are common in patients with schizophrenia. This article reviews the principles that have been developed by the STAY (the Six principles to improve Treatment Adherence in Your patients) initiative to help patients with schizophrenia adhere to their medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cañas F, Alptekin K, Azorin JM, et al. Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Invest. 2013;33(2):97–107.

    Article  Google Scholar 

  2. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46.

    PubMed  Google Scholar 

  3. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909.

    Article  PubMed  Google Scholar 

  4. Ascher-Svanum H, Faries BE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–60.

    Article  PubMed  Google Scholar 

  5. Weiden PJ, Zygmut A. Medication noncompliance in schizophrenia. Part I: assessment. J Pract Psychiatry Behav Health. 1997;3:106–10.

    Google Scholar 

  6. Perkins DO, Hongbin G, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106–13.

    Article  PubMed  CAS  Google Scholar 

  7. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003;33(7):1149–60.

    Article  PubMed  Google Scholar 

  8. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161(2):235–47.

    Article  PubMed  Google Scholar 

  9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.

    Article  PubMed  CAS  Google Scholar 

  10. Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2–3):109–13.

    Article  PubMed  Google Scholar 

  11. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.

    Article  PubMed  CAS  Google Scholar 

  12. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–7.

    Article  PubMed  CAS  Google Scholar 

  13. Dolder CR, Lacro JP, Warren KA, et al. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J Clin Psychopharmacol. 2004;24(4):404–9.

    Article  PubMed  Google Scholar 

  14. Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res. 2008;100(1–3):60–9.

    Article  PubMed  Google Scholar 

  15. Clayton CD, Veach J, Macfadden W, et al. Assessment of clinician awareness of nonadherence using a new structured rating scale. J Psychiatr Pract. 2010;16(3):164–9.

    Article  PubMed  Google Scholar 

  16. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345–9.

    Article  PubMed  CAS  Google Scholar 

  17. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37(6):243–65.

    Article  PubMed  CAS  Google Scholar 

  18. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia: relationship to course and outcome. Arch Gen Psychiatry. 1990;47(3):228–36.

    Article  PubMed  CAS  Google Scholar 

  19. Fleischhacker WW, Hofer A, Hummer M. Managing schizophrenia: the compliance challenge. 2nd ed. London: Science Press; 2007.

    Google Scholar 

  20. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):9–14.

    PubMed  CAS  Google Scholar 

  21. Smerud PE, Rosenfarb IS. The therapeutic alliance and family psychoeducation in the treatment of schizophrenia: an exploratory prospective change process study. J Consult Clin Psychol. 2008;76(3):505–10.

    Article  PubMed  Google Scholar 

  22. Pitschel-Walz G, Leucht S, Bäuml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis. Schizophr Bull. 2001;27(1):73–92.

    Article  PubMed  CAS  Google Scholar 

  23. Dolder CR, Lacro JP, Leckband S, et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol. 2003;23(4):389–99.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from Clinical Drug Investigation; 2013;33(2):97–107 [1]. The preparation of this article was not supported by any external funding; however, Janssen funded the development of the STAY initiative and editorial and writing support for the original article [1].

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Following the six principles developed by the STAY initiative may improve treatment adherence in patients with schizophrenia. Drugs Ther Perspect 29, 287–290 (2013). https://doi.org/10.1007/s40267-013-0066-4

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0066-4

    Keywords

    Search

    Navigation